1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

International Biotechnology Trust Plc Buys ChemoCentryx Inc, PTC Therapeutics Inc, Zogenix Inc, Sells Regeneron Pharmaceuticals Inc, Stemline Therapeutics Inc, Illumina Inc

Investment company International Biotechnology Trust Plc (Current Portfolio) buys ChemoCentryx Inc, PTC Therapeutics Inc, Zogenix Inc, Biomarin Pharmaceutical Inc, Eli Lilly and Co, sells Regeneron Pharmaceuticals Inc, Stemline Therapeutics Inc, Illumina Inc, NovoCure, Sangamo Therapeutics Inc during the 3-months ended 2020Q1, according to the most recent filings of the investment company, International Biotechnology Trust Plc. As of 2020Q1, International Biotechnology Trust Plc owns 56 stocks with a total value of $219 million. These are the details of the buys and sells.

For the details of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's stock buys and sells, go to https://www.gurufocus.com/guru/international+biotechnology+trust+plc/current-portfolio/portfolio

These are the top 5 holdings of INTERNATIONAL BIOTECHNOLOGY TRUST PLC
  1. Vertex Pharmaceuticals Inc (VRTX) - 77,822 shares, 8.44% of the total portfolio. Shares reduced by 16.7%
  2. Gilead Sciences Inc (GILD) - 237,284 shares, 8.08% of the total portfolio. Shares reduced by 19.09%
  3. Biogen Inc (BIIB) - 45,700 shares, 6.59% of the total portfolio.
  4. Biomarin Pharmaceutical Inc (BMRN) - 169,784 shares, 6.54% of the total portfolio. Shares added by 62.81%
  5. ACADIA Pharmaceuticals Inc (ACAD) - 337,000 shares, 6.49% of the total portfolio. Shares added by 0.30%
New Purchase: ChemoCentryx Inc (CCXI)

International Biotechnology Trust Plc initiated holding in ChemoCentryx Inc. The purchase prices were between $32.73 and $50.78, with an estimated average price of $42.52. The stock is now traded at around $53.80. The impact to a portfolio due to this purchase was 3.48%. The holding were 190,000 shares as of .

New Purchase: Eli Lilly and Co (LLY)

International Biotechnology Trust Plc initiated holding in Eli Lilly and Co. The purchase prices were between $119.05 and $147.35, with an estimated average price of $137.4. The stock is now traded at around $159.23. The impact to a portfolio due to this purchase was 1.26%. The holding were 20,000 shares as of .

New Purchase: Enanta Pharmaceuticals Inc (ENTA)

International Biotechnology Trust Plc initiated holding in Enanta Pharmaceuticals Inc. The purchase prices were between $40.22 and $62, with an estimated average price of $53.48. The stock is now traded at around $55.20. The impact to a portfolio due to this purchase was 1.09%. The holding were 46,500 shares as of .

New Purchase: Principia Biopharma Inc (PRNB)

International Biotechnology Trust Plc initiated holding in Principia Biopharma Inc. The purchase prices were between $43.5 and $74.09, with an estimated average price of $58.41. The stock is now traded at around $64.11. The impact to a portfolio due to this purchase was 0.62%. The holding were 23,100 shares as of .

New Purchase: Immunomedics Inc (IMMU)

International Biotechnology Trust Plc initiated holding in Immunomedics Inc. The purchase prices were between $9.48 and $21.16, with an estimated average price of $16.95. The stock is now traded at around $33.96. The impact to a portfolio due to this purchase was 0.44%. The holding were 72,000 shares as of .

New Purchase: Alkermes PLC (ALKS)

International Biotechnology Trust Plc initiated holding in Alkermes PLC. The purchase prices were between $13.06 and $21.24, with an estimated average price of $17.91. The stock is now traded at around $15.27. The impact to a portfolio due to this purchase was 0.34%. The holding were 52,000 shares as of .

Added: PTC Therapeutics Inc (PTCT)

International Biotechnology Trust Plc added to a holding in PTC Therapeutics Inc by 135.96%. The purchase prices were between $32.37 and $59.36, with an estimated average price of $50.48. The stock is now traded at around $48.83. The impact to a portfolio due to this purchase was 3.15%. The holding were 269,000 shares as of .

Added: Zogenix Inc (ZGNX)

International Biotechnology Trust Plc added to a holding in Zogenix Inc by 559.95%. The purchase prices were between $17.8 and $56.59, with an estimated average price of $36.87. The stock is now traded at around $27.60. The impact to a portfolio due to this purchase was 2.69%. The holding were 281,797 shares as of .

Added: Biomarin Pharmaceutical Inc (BMRN)

International Biotechnology Trust Plc added to a holding in Biomarin Pharmaceutical Inc by 62.81%. The purchase prices were between $71.37 and $96.85, with an estimated average price of $86.22. The stock is now traded at around $93.74. The impact to a portfolio due to this purchase was 2.52%. The holding were 169,784 shares as of .

Added: Incyte Corp (INCY)

International Biotechnology Trust Plc added to a holding in Incyte Corp by 55.47%. The purchase prices were between $63.18 and $87.32, with an estimated average price of $75.84. The stock is now traded at around $96.12. The impact to a portfolio due to this purchase was 1.18%. The holding were 99,500 shares as of .

Added: uniQure NV (QURE)

International Biotechnology Trust Plc added to a holding in uniQure NV by 103.70%. The purchase prices were between $40.01 and $73.97, with an estimated average price of $57.92. The stock is now traded at around $58.33. The impact to a portfolio due to this purchase was 0.3%. The holding were 27,500 shares as of .

Added: Mirati Therapeutics Inc (MRTX)

International Biotechnology Trust Plc added to a holding in Mirati Therapeutics Inc by 22.28%. The purchase prices were between $69.78 and $128.86, with an estimated average price of $90.44. The stock is now traded at around $103.37. The impact to a portfolio due to this purchase was 0.28%. The holding were 43,900 shares as of .

Sold Out: Regeneron Pharmaceuticals Inc (REGN)

International Biotechnology Trust Plc sold out a holding in Regeneron Pharmaceuticals Inc. The sale prices were between $336.18 and $494.43, with an estimated average price of $411.31.

Sold Out: Stemline Therapeutics Inc (STML)

International Biotechnology Trust Plc sold out a holding in Stemline Therapeutics Inc. The sale prices were between $3.41 and $10.79, with an estimated average price of $6.56.

Sold Out: Illumina Inc (ILMN)

International Biotechnology Trust Plc sold out a holding in Illumina Inc. The sale prices were between $209.2 and $335.53, with an estimated average price of $288.89.

Sold Out: NovoCure Ltd (NVCR)

International Biotechnology Trust Plc sold out a holding in NovoCure Ltd. The sale prices were between $57.05 and $95.75, with an estimated average price of $79.54.

Sold Out: Sangamo Therapeutics Inc (SGMO)

International Biotechnology Trust Plc sold out a holding in Sangamo Therapeutics Inc. The sale prices were between $5.05 and $8.85, with an estimated average price of $7.45.

Sold Out: BeiGene Ltd (BGNE)

International Biotechnology Trust Plc sold out a holding in BeiGene Ltd. The sale prices were between $121.84 and $173.19, with an estimated average price of $156.97.

Reduced: Alnylam Pharmaceuticals Inc (ALNY)

International Biotechnology Trust Plc reduced to a holding in Alnylam Pharmaceuticals Inc by 48.5%. The sale prices were between $93.12 and $133.99, with an estimated average price of $115.68. The stock is now traded at around $139.28. The impact to a portfolio due to this sale was -0.87%. International Biotechnology Trust Plc still held 22,300 shares as of .

Reduced: Acceleron Pharma Inc (XLRN)

International Biotechnology Trust Plc reduced to a holding in Acceleron Pharma Inc by 68.42%. The sale prices were between $50.95 and $95.31, with an estimated average price of $77.26. The stock is now traded at around $102.11. The impact to a portfolio due to this sale was -0.75%. International Biotechnology Trust Plc still held 18,000 shares as of .

Reduced: Nektar Therapeutics (NKTR)

International Biotechnology Trust Plc reduced to a holding in Nektar Therapeutics by 52.14%. The sale prices were between $14.47 and $27.96, with an estimated average price of $20.7. The stock is now traded at around $22.02. The impact to a portfolio due to this sale was -0.57%. International Biotechnology Trust Plc still held 67,000 shares as of .

Reduced: Sarepta Therapeutics Inc (SRPT)

International Biotechnology Trust Plc reduced to a holding in Sarepta Therapeutics Inc by 29.93%. The sale prices were between $82.38 and $131.64, with an estimated average price of $114.91. The stock is now traded at around $141.25. The impact to a portfolio due to this sale was -0.56%. International Biotechnology Trust Plc still held 28,100 shares as of .



Here is the complete portfolio of INTERNATIONAL BIOTECHNOLOGY TRUST PLC. Also check out:

1. INTERNATIONAL BIOTECHNOLOGY TRUST PLC's Undervalued Stocks
2. INTERNATIONAL BIOTECHNOLOGY TRUST PLC's Top Growth Companies, and
3. INTERNATIONAL BIOTECHNOLOGY TRUST PLC's High Yield stocks
4. Stocks that INTERNATIONAL BIOTECHNOLOGY TRUST PLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)